Abbott Could Reach New Highs On Xience Prime

By EnhydrisPECorp:ACADIA Pharmaceuticals Inc. (ACAD) recently announced successful top-line results from its Phase III trial evaluating pimavanserin in patients with Parkinson's disease psychosis (PDP).

By Income Hunter:Abbott (ABT) recently released the findings from a three year study evaluating its drug Humira in patients with moderate to severe Ulcerative Colitis. At 60 weeks, the remission rate was an incredible 55% of these refractory cases.

Dividend Growth Investor submits:Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.

The Burrill Report submits: Antisoma (ATSMY.PK) discontinued a late-stage trial of its experimental drug for previously untreated non-small cell lung cancer patients saying a continuation of the trial “would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting.” The news sent shares in the company tumbling down 75 percent and was followed by the departure of the company’s COO Ursula Ney.

By Mel Daris:Abbott Laboratories (ABT) is facing enormous costs for its decisions in marketing Depakote, its anti-seizure drug. The company marketed Depakote for uses it had not been approved for, and it downplayed the potential risks involved with taking the drug.

By John Mylant: Abbott Laboratories (ABT) continues to climb after it split off into Abbvie (ABBV). The company has a number of different divisions including nutrition, diagnostics, generic pharmaceuticals, and medical devices.

ByCarl Cachia:Acadia Pharmaceuticals (ACAD) is a stock I have been following for some time. I have been working in the medical field for the past 15 years, and having first-hand experience with patients with Parkinson's disease, I can say that the potential of ACAD's drug Pimavanserin is massive and can reap huge benefits to investors in the long term. The story